Neuronetics Q3 2024 Earnings: Misses Expectations Amid Strategic Moves

Neuronetics, Inc. (STIM), a commercial-stage medical technology company specializing in neurohealth therapies, reported its third-quarter 2024 earnings on November 12, 2024. While the company's revenue increased by 4% year-over-year, it fell short of analyst expectations, raising concerns about its financial performance. This article examines Neuronetics' Q3 2024 earnings, strategic initiatives, and the potential impact on investors.

Neuronetics' total revenue for the quarter reached $18.5 million, up from $17.9 million in the same period last year. However, this figure fell short of the analyst estimate of $19.13 million. The company's U.S. NeuroStar Advanced Therapy System revenue rose by 14% to $4.1 million, driven by increased system shipments. U.S. treatment session revenue also grew by 2% to $13.3 million. Despite these gains, international revenues declined by 10%, contributing to the overall revenue miss.

The company's net loss widened to $13.3 million, or $0.44 per share, compared to a net loss of $9.4 million, or $0.33 per share, in the third quarter of 2023. This result was below the analyst estimate of a $0.23 loss per share. Neuronetics' EBITDA also worsened, recording a loss of $11.6 million compared to $7.7 million in the previous year.

Neuronetics' gross margin improved significantly to 75.6% from 65.8% in the prior year, driven by a favorable product mix and the absence of one-time manufacturing costs and inventory impairments from 2023. However, operating expenses increased by 5% to $21.7 million, impacting the overall profitability.

Neuronetics' cash and cash equivalents stood at $20.9 million as of September 30, 2024, a significant decrease from $59.7 million at the end of 2023. This reduction highlights the company's ongoing cash flow challenges, which are critical for sustaining operations and funding strategic initiatives.

One of Neuronetics' strategic moves was the acquisition of Greenbrook TMS, approved by stockholders on November 8, 2024. This acquisition positions Neuronetics as one of the largest and most innovative mental health care providers in the United States. The strategic combination is expected to enhance Neuronetics' ability to expand access to mental health solutions through a unified commercial organization, while also creating opportunities to accelerate the rollout of additional services like SPRAVATO® across the network.



In conclusion, Neuronetics' Q3 2024 earnings report reflects both progress and challenges. The revenue growth and improved gross margin are positive indicators, yet the increased net loss and cash flow issues pose significant concerns. The strategic acquisition of Greenbrook TMS is a pivotal step towards enhancing market presence and operational efficiency, potentially leading to improved financial outcomes in the future. Investors should closely monitor Neuronetics' performance and the integration of Greenbrook TMS to assess the company's long-term prospects.